Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heated Cisplatin after EPP for Mesothelioma
NCT00165516Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2004
- Primary completion
- Jul 2006
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in malignant pleural mesothelioma (MPM), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Tumor Recurrence and Overall Survival. Started Jan 2004; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00165516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165516.